<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421508</url>
  </required_header>
  <id_info>
    <org_study_id>PULSE-CVD19-001</org_study_id>
    <nct_id>NCT04421508</nct_id>
  </id_info>
  <brief_title>A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19</brief_title>
  <acronym>COViNOX</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellerophon Pulse Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellerophon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of
      pulsed inhaled iNO compared to placebo in subjects with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to assess the efficacy and
      safety of pulsed iNO compared to placebo in subjects with COVID-19 who are hospitalized and
      require supplemental oxygen without assisted ventilation. Subjects will be randomized to
      receive placebo or iNO125 mcg/kg ideal body weight (IBW)/hour 24 hours daily up to 14 days or
      until resolution or discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who died or had respiratory failure</measure>
    <time_frame>Through Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical status using National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal scale</measure>
    <time_frame>Day 7, 14, 28 and day of discharge</time_frame>
    <description>The assessment of clinical status at the first assessment of a study day. The scale is: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject to recover, defined as return to room air or baseline O2, or discharged alive</measure>
    <time_frame>Through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects discharged alive from hospital</measure>
    <time_frame>Through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality - all cause and cardiopulmonary</measure>
    <time_frame>Through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a negative conversion of reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal swab</measure>
    <time_frame>Through Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of subjects with adverse events leading to study drug discontinuation</measure>
    <time_frame>Through Day 28</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>Coronavirus</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulsed inhaled iNO 125 mcg/kg IBW/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Pulsed inhaled N2, 99.999% gas</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>INOpulse</intervention_name>
    <description>Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.</description>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  At least 18 years old

          -  Subjects must be hospitalized and have the following:

               -  proven or high suspicion of SARS-CoV-2 infection and,

               -  requiring oxygen supplementation defined as:

               -  SpO2 ≤ 92% regardless of supplemental oxygen (ie on room air or on oxygen), or

               -  SpO2 ≥ 92% on supplemental O2 and in the opinion of the Investigator it is not
                  safe to decrease or remove the supplemental oxygen

               -  require supplemental oxygen of no more than 10 L/minute, and

               -  radiologic suspected or proven COVID-19 pneumonitis (chest x-ray or CT scan)

          -  Female subjects must have a negative pregnancy test

          -  Willing and able to comply with the treatment schedule and study procedures

        Exclusion Criteria:

          -  Participating in another clinical trial of an investigational treatment for COVID-19

          -  Methemoglobin &gt; 3%

          -  Evidence of severe multi organ failure

          -  Use of assisted ventilation prior to initiation of iNO

          -  Pregnancy or positive pregnancy test pre-dose

          -  Open tracheostomy

          -  Chronic use of a nitric oxide donor agent such as nitroglycerin or drugs known to
             increase methemoglobin such as lidocaine, prilocaine, benzocaine, nitroprusside,
             isosorbide, or dapsone at screening

          -  History or clinical evidence of systolic heart failure, left ventricular dysfunction
             (LVEF &lt;40%)

          -  Subjects reporting massive hemoptysis associated with the current illness or with
             radiologically proven pulmonary embolus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wassim Fares, MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>Bellerophon Pulse Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Parker</last_name>
    <phone>908-574-4713</phone>
    <email>valerie.parker@bellerophon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Alamo</last_name>
    <phone>908-574-4768</phone>
    <email>michelle.alamo@bellerophon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Valencia, MPH, MBEMH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Zion Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Rodriguez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Rodriguez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Simonet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Lung Research Center (St. Luke's)</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Shipp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Trejo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brougher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Health St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Krueger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delores Ferhele</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Younes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>INOVA</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martha Alemayehu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lincoln</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lincoln</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chippenham Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lincoln</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lincoln</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lincoln</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johnston-Willis Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lincoln</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>Sars-CoV-2</keyword>
  <keyword>iNO</keyword>
  <keyword>INOpulse</keyword>
  <keyword>Severe Acute Respiratory Syndrome (SARS) Pneumonia</keyword>
  <keyword>Severe Acute Respiratory Syndrome Coronavirus 2</keyword>
  <keyword>SARS-CoV 2</keyword>
  <keyword>COViNOX</keyword>
  <keyword>pulsed inhaled nitric oxide</keyword>
  <keyword>inhaled nitric oxide</keyword>
  <keyword>portable pulsed inhaled nitric oxide</keyword>
  <keyword>nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

